🇺🇸 FDA
Patent

US 9517276

Compositions and methods for conjugating activatable antibodies

granted A61KA61K2039/505A61K39/3955

Quick answer

US patent 9517276 (Compositions and methods for conjugating activatable antibodies) held by CytomX Therapeutics, Inc. expires Mon Dec 08 2036 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
CytomX Therapeutics, Inc.
Grant date
Tue Dec 13 2016 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Dec 08 2036 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
31
CPC classes
A61K, A61K2039/505, A61K39/3955, A61K47/68031, A61K47/6851